Lyra Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Lyra Therapeutics has a total shareholder equity of $31.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $94.6M and $63.6M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$67.50m |
| Eşitlik | US$30.98m |
| Toplam yükümlülükler | US$63.61m |
| Toplam varlıklar | US$94.58m |
Son finansal sağlık güncellemeleri
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: LYRA's short term assets ($69.4M) exceed its short term liabilities ($19.3M).
Uzun Vadeli Yükümlülükler: LYRA's short term assets ($69.4M) exceed its long term liabilities ($44.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: LYRA is debt free.
Borcun Azaltılması: LYRA has no debt compared to 5 years ago when its debt to equity ratio was 10.7%.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: LYRA has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: LYRA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.9% each year